Latest news with #EvolentHealth
Yahoo
27-05-2025
- Business
- Yahoo
Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Healthcare Technology for Providers company Evolent Health (NYSE:EVH) jumped 5.6%. Is now the time to buy Evolent Health? Access our full analysis report here, it's free. Generic Pharmaceuticals company Amphastar Pharmaceuticals (NASDAQ:AMPH) jumped 5%. Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here, it's free. Satellite Telecommunication Services company Iridium (NASDAQ:IRDM) jumped 5.7%. Is now the time to buy Iridium? Access our full analysis report here, it's free. Advertising & Marketing Services company Magnite (NASDAQ:MGNI) jumped 5.6%. Is now the time to buy Magnite? Access our full analysis report here, it's free. Iridium's shares are quite volatile and have had 17 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Iridium is down 11.2% since the beginning of the year, and at $26.27 per share, it is trading 21.7% below its 52-week high of $33.57 from October 2024. Investors who bought $1,000 worth of Iridium's shares 5 years ago would now be looking at an investment worth $1,099. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
Yahoo
08-05-2025
- Business
- Yahoo
Evolent Health (NYSE:EVH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations
Healthcare solutions company Evolent Health (NYSE:EVH) reported Q1 CY2025 results beating Wall Street's revenue expectations , but sales fell by 24.4% year on year to $483.6 million. Revenue guidance for the full year exceeded analysts' estimates, but next quarter's guidance of $455 million was less impressive, coming in 9.4% below expectations. Its non-GAAP profit of $0.06 per share was 37.7% below analysts' consensus estimates. Is now the time to buy Evolent Health? Find out in our full research report. Revenue: $483.6 million vs analyst estimates of $461.2 million (24.4% year-on-year decline, 4.9% beat) Adjusted EPS: $0.06 vs analyst expectations of $0.10 (37.7% miss) Adjusted EBITDA: $36.86 million vs analyst estimates of $33.82 million (7.6% margin, 9% beat) The company reconfirmed its revenue guidance for the full year of $2.09 billion at the midpoint EBITDA guidance for the full year is $150 million at the midpoint, in line with analyst expectations Operating Margin: -0.3%, up from -2.1% in the same quarter last year Free Cash Flow was -$4.03 million compared to -$438,000 in the same quarter last year Sales Volumes fell 99.9% year on year (19.5% in the same quarter last year) Market Capitalization: $1.21 billion Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA. We continue to see a very strong selling environment and we achieved significant organic growth with five new revenue agreements announced today. Operationally, we continue scaling our innovative oncology condition management solution to help Evolent further impact specialty care member experience, costs and outcomes. Performance Suite margins, including leading indicators on utilization, and AI-based automation initiatives, like Auth Intel, are both currently tracking favorably. From an innovation perspective we remain focused on improving member and provider experience in specialty care, while continuing to manage affordability for the system – a combination we believe Evolent is uniquely positioned to deliver. In the time ahead we'll remain disciplined in capital allocation, prioritizing cash generation and debt paydown. I am proud of our recent progress and I believe that our strong pipeline, low market penetration, innovative product stack and highly engaged team of 4,500 professionals, positions Evolent to deliver sustained value to our shareholders, partners and members in the short and long term." Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions. A company's long-term sales performance can indicate its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Evolent Health grew its sales at an excellent 22.5% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Evolent Health's annualized revenue growth of 27.2% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. We can dig further into the company's revenue dynamics by analyzing its number of average lives on platform, which reached 77,079 in the latest quarter. Over the last two years, Evolent Health's average lives on platform averaged 134% year-on-year growth. Because this number is better than its revenue growth, we can see the company's average selling price decreased. This quarter, Evolent Health's revenue fell by 24.4% year on year to $483.6 million but beat Wall Street's estimates by 4.9%. Company management is currently guiding for a 29.7% year-on-year decline in sales next quarter. Looking further ahead, sell-side analysts expect revenue to decline by 8.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and implies its products and services will face some demand challenges. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. Although Evolent Health broke even this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 5% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. On the plus side, Evolent Health's operating margin rose by 26.9 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its past improvements as the company's margin was relatively unchanged on two-year basis. Evolent Health's operating margin was negative 0.3% this quarter. The company's consistent lack of profits raise a flag. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Evolent Health's full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it's at a critical moment in its life. In Q1, Evolent Health reported EPS at $0.06, down from $0.34 in the same quarter last year. This print missed analysts' estimates, but we care more about long-term EPS growth than short-term movements. Over the next 12 months, Wall Street expects Evolent Health's full-year EPS of $0.38 to grow 46.3%. We enjoyed seeing Evolent Health beat analysts' revenue expectations this quarter. We were also glad its full-year revenue guidance slightly exceeded Wall Street's estimates. On the other hand, its revenue guidance for next quarter missed significantly and its EPS fell short of Wall Street's estimates. Overall, this was a mixed quarter. The stock remained flat at $10.72 immediately following the results. The latest quarter from Evolent Health's wasn't that good. One earnings report doesn't define a company's quality, though, so let's explore whether the stock is a buy at the current price. When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
Washington Post
08-05-2025
- Business
- Washington Post
Evolent Health: Q1 Earnings Snapshot
ARLINGTON, Va. — ARLINGTON, Va. — Evolent Health Inc. (EVH) on Thursday reported a loss of $64.6 million in its first quarter. On a per-share basis, the Arlington, Virginia-based company said it had a loss of 63 cents. Earnings, adjusted for non-recurring costs and stock option expense, came to 6 cents per share.
Yahoo
08-05-2025
- Business
- Yahoo
Evolent Health (EVH) Q1 Earnings Report Preview: What To Look For
Healthcare solutions company Evolent Health (NYSE:EVH) will be announcing earnings results tomorrow after market close. Here's what investors should know. Evolent Health missed analysts' revenue expectations by 0.7% last quarter, reporting revenues of $646.5 million, up 16.3% year on year. It was a softer quarter for the company, with a significant miss of analysts' EPS estimates and EBITDA guidance for next quarter missing analysts' expectations significantly. Is Evolent Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Evolent Health's revenue to decline 27.9% year on year to $461.2 million, a reversal from the 49.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.10 per share. Evolent Health Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Evolent Health has missed Wall Street's revenue estimates three times over the last two years. Looking at Evolent Health's peers in the healthcare technology segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Premier's revenues decreased 8.9% year on year, beating analysts' expectations by 7.4%, and Omnicell reported revenues up 9.6%, topping estimates by 3.7%. Read our full analysis of Premier's results here and Omnicell's results here. There has been positive sentiment among investors in the healthcare technology segment, with share prices up 5.9% on average over the last month. Evolent Health is up 7.9% during the same time and is heading into earnings with an average analyst price target of $15.15 (compared to the current share price of $10.30). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
29-04-2025
- Business
- Yahoo
Winners And Losers Of Q4: Evolent Health (NYSE:EVH) Vs The Rest Of The Healthcare Technology for Providers Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let's take a look at how Evolent Health (NYSE:EVH) and the rest of the healthcare technology for providers stocks fared in Q4. The healthcare technology industry focuses on delivering software, data analytics, and workflow solutions to hospitals, clinics, and other care facilities. These companies enable providers to streamline operations, optimize patient outcomes, and transition to value-based care models. They boast subscription-based revenues or long-term contracts, providing financial stability and growth potential. However, they face challenges such as lengthy sales cycles, significant upfront investment in technology development, and reliance on providers' adoption of new tools, which can be hindered by budget constraints or resistance to change. Over the next few years, the sector is poised for growth as providers increasingly prioritize digital transformation and efficiency in response to rising healthcare costs and patient demand for seamless care. Tailwinds include the growing adoption of AI-driven tools for patient engagement and operational improvements, government incentives for digitization, and the expansion of telehealth and remote patient monitoring. However, headwinds such as tightening hospital budgets, cybersecurity threats, and the fragmented nature of healthcare systems could slow adoption. The 6 healthcare technology for providers stocks we track reported a slower Q4. As a group, revenues beat analysts' consensus estimates by 3.1% while next quarter's revenue guidance was 0.7% below. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 11% since the latest earnings results. Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions. Evolent Health reported revenues of $646.5 million, up 16.3% year on year. This print fell short of analysts' expectations by 0.7%. Overall, it was a softer quarter for the company with a significant miss of analysts' EPS estimates and EBITDA guidance for next quarter missing analysts' expectations significantly. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent delivered fourth quarter and 2024 full-year results within the outlook range we provided in November, despite continued elevated oncology costs during the quarter. We also ended the year with 100% retention across our top customers which together represent over 90% of our 2024 revenue. Looking ahead, the recent changes we made in certain of our Performance Suite contracts as well as our assumptions for medical cost inflation make us feel confident in our financial outlook. Finally, we believe Evolent remains an incredibly unique asset; We have a strong team, a product that our customers value and a clinical approach that both manages healthcare affordability while also enabling the kind of care we would want for our family members." Evolent Health delivered the weakest performance against analyst estimates and weakest full-year guidance update of the whole group. Unsurprisingly, the stock is down 16.1% since reporting and currently trades at $9. Read our full report on Evolent Health here, it's free. Founded in 2005 to streamline the traditionally paper-heavy patient check-in process, Phreesia (NYSE:PHR) provides software solutions that automate patient intake, registration, and payment processes for healthcare organizations while improving patient engagement in their care. Phreesia reported revenues of $109.7 million, up 15.4% year on year, outperforming analysts' expectations by 0.7%. The business had a strong quarter with an impressive beat of analysts' EPS estimates and full-year EBITDA guidance topping analysts' expectations. The market seems content with the results as the stock is up 2.6% since reporting. It currently trades at $24.49. Is now the time to buy Phreesia? Access our full analysis of the earnings results here, it's free. Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency. Omnicell reported revenues of $306.9 million, up 18.6% year on year, exceeding analysts' expectations by 2.2%. Still, it was a slower quarter as it posted EBITDA guidance for next quarter missing analysts' expectations and a miss of analysts' full-year EPS guidance estimates. As expected, the stock is down 29.3% since the results and currently trades at $31.39. Read our full analysis of Omnicell's results here. Operating one of the largest healthcare group purchasing organizations in the United States with over 4,350 hospital members, Premier (NASDAQ:PINC) is a technology-driven healthcare improvement company that helps hospitals, health systems, and other providers reduce costs and improve clinical outcomes. Premier reported revenues of $240.3 million, down 14.2% year on year. This number met analysts' expectations. Aside from that, it was a slower quarter as it recorded a significant miss of analysts' EPS estimates and full-year revenue guidance missing analysts' expectations. Premier had the slowest revenue growth among its peers. The stock is down 7.1% since reporting and currently trades at $20.82. Read our full, actionable report on Premier here, it's free. Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ:ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models. Astrana Health reported revenues of $665.2 million, up 88.4% year on year. This result beat analysts' expectations by 6.9%. Taking a step back, it was a mixed quarter as it also produced full-year revenue guidance beating analysts' expectations. Astrana Health pulled off the fastest revenue growth and highest full-year guidance raise among its peers. The stock is down 12.1% since reporting and currently trades at $30.50. Read our full, actionable report on Astrana Health here, it's free. In response to the Fed's rate hikes in 2022 and 2023, inflation has been gradually trending down from its post-pandemic peak, trending closer to the Fed's 2% target. Despite higher borrowing costs, the economy has avoided flashing recessionary signals. This is the much-desired soft landing that many investors hoped for. The recent rate cuts (0.5% in September and 0.25% in November 2024) have bolstered the stock market, making 2024 a strong year for equities. Donald Trump's presidential win in November sparked additional market gains, sending indices to record highs in the days following his victory. However, debates continue over possible tariffs and corporate tax adjustments, raising questions about economic stability in 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
